MX2020006451A - Tratamiento de la fibrosis con inositol. - Google Patents
Tratamiento de la fibrosis con inositol.Info
- Publication number
- MX2020006451A MX2020006451A MX2020006451A MX2020006451A MX2020006451A MX 2020006451 A MX2020006451 A MX 2020006451A MX 2020006451 A MX2020006451 A MX 2020006451A MX 2020006451 A MX2020006451 A MX 2020006451A MX 2020006451 A MX2020006451 A MX 2020006451A
- Authority
- MX
- Mexico
- Prior art keywords
- fibrosis
- inositol
- treatment
- reactive
- subject
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere al uso médico de inositol para el tratamiento de la fibrosis muscular reactiva, por ejemplo, fibrosis cardiaca reactiva, en un sujeto. La presente invención se refiere además a métodos para el tratamiento de la fibrosis muscular reactiva, por ejemplo, fibrosis cardiaca reactiva mediante la administración de inositol a un sujeto.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT201700148902 | 2017-12-22 | ||
PCT/EP2018/086182 WO2019122119A1 (en) | 2017-12-22 | 2018-12-20 | Treatment of fibrosis with inositol |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020006451A true MX2020006451A (es) | 2020-11-06 |
Family
ID=61731767
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020006451A MX2020006451A (es) | 2017-12-22 | 2018-12-20 | Tratamiento de la fibrosis con inositol. |
Country Status (7)
Country | Link |
---|---|
US (1) | US20200390723A1 (es) |
EP (1) | EP3727359B1 (es) |
BR (1) | BR112020012687A2 (es) |
CA (1) | CA3085612A1 (es) |
MA (1) | MA51276A (es) |
MX (1) | MX2020006451A (es) |
WO (1) | WO2019122119A1 (es) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6245755B1 (en) * | 1992-04-21 | 2001-06-12 | Curators Of The Unversity Of Missouri | Use of aldosterone antagonists to inhibit myocardial fibrosis |
EP0971641A4 (en) | 1997-04-03 | 2003-08-13 | Point Biomedical Corp | SYSTEM FOR THE ADMINISTRATION OF AN INTRAVESICAL MEDICINAL PRODUCT |
RU2563127C2 (ru) * | 2009-07-07 | 2015-09-20 | Нормоксис, Инк, | Способ уменьшения мультилекарственной резистентности с использованием трипирофосфата инозита |
ITUA20163025A1 (it) * | 2016-04-29 | 2017-10-29 | Sochim Int S P A | Composizione per il trattamento della sindrome dell’ovaio policistico |
-
2018
- 2018-12-20 BR BR112020012687-0A patent/BR112020012687A2/pt not_active Application Discontinuation
- 2018-12-20 US US16/955,220 patent/US20200390723A1/en not_active Abandoned
- 2018-12-20 MX MX2020006451A patent/MX2020006451A/es unknown
- 2018-12-20 MA MA051276A patent/MA51276A/fr unknown
- 2018-12-20 EP EP18822360.6A patent/EP3727359B1/en active Active
- 2018-12-20 WO PCT/EP2018/086182 patent/WO2019122119A1/en unknown
- 2018-12-20 CA CA3085612A patent/CA3085612A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MA51276A (fr) | 2021-04-21 |
CA3085612A1 (en) | 2019-06-27 |
EP3727359A1 (en) | 2020-10-28 |
EP3727359B1 (en) | 2024-04-17 |
US20200390723A1 (en) | 2020-12-17 |
WO2019122119A1 (en) | 2019-06-27 |
EP3727359C0 (en) | 2024-04-17 |
BR112020012687A2 (pt) | 2020-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019502793A1 (en) | Aadc polynucleotides for the treatment of parkinson`s disease | |
MX2019009443A (es) | Metodos para tratar la influenza. | |
MX2017005834A (es) | Polinucleotidos aad para el tratamiento de la enfermedad de parkinson. | |
PH12017500746B1 (en) | Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease | |
MX2017004471A (es) | Compuestos de triazolopiridina y métodos para el tratamiento de fibrosis cística. | |
PH12018500315A1 (en) | Fumagillol heterocyclic compounds and methods of making and using same | |
PH12018500762A1 (en) | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof | |
SG10201804034QA (en) | Methods for treating hypotension | |
EA033446B1 (ru) | Гетероциклическое соединение для лечения дегенерации желтого пятна и/или болезни штаргардта | |
MX2019003710A (es) | Compuestos y metodos de p2x3 y/o p2x2/3. | |
MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
TW201613544A (en) | Treatment device and chair | |
EA202193276A1 (ru) | Способы лечения холангиокарциномы | |
MX2018014129A (es) | Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato. | |
MX2019000677A (es) | Células miméticas de células b. | |
MX2019004804A (es) | Tratamiento para el prurigo nodula. | |
TW201613639A (en) | Methods for treating cardiovascular diseases | |
MY187167A (en) | Medical treatments based on anamorelin | |
MX2020003049A (es) | Semaglutida en la terapia medica. | |
MX2017004842A (es) | Levosimendan para uso en el tratamiento de enfermedades de las neuronas motoras (por ejemplo esclerosis lateral amiotrofica). | |
TW201613569A (en) | Composition consisting of kukoamine A and/or kukoamine B and method of using thereof | |
WO2015142865A3 (en) | Metakaryocidal treatments | |
MX2016012758A (es) | Composicion hiperosmolar de acido hialuronico. | |
MX2021014120A (es) | Tratamiento de los sintomas asociados a terapia privacion de androgenos. | |
MX2018011379A (es) | Tratamiento del prurito uremico. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB | Transfer or rights |
Owner name: LO.LI. PHARMA S.R.L. |